Details

Autor(en) / Beteiligte

• Zemanova, Milada
• Pirker, Robert
• Petruzelka, Lubos
• Zbozínkova, Zuzana
• Jovanovic, Dragana
• Rajer, Mirjana
• Bogos, Krisztina
• Purkalne, Gunta
• Ceriman, Vesna
• Chaudhary, Subhash
• Richter, Igor
• Kufa, Jirí
• Jakubikova, Lenka
• Zemaitis, Marius
• Cernovska, Marketa
• Koubkova, Leona
• Vilasova, Zdenka
• Dieckmann, Karin
• Farkas, Attila
• Spasic, Jelena
• Fröhlich, Katerina
• Tiefenbacher, Andreas
• Hollosi, Virag
• Kultan, Juraj
• Kolarová, Iveta
• Votruba, Jiri

Titel

Care of patients with non-small-cell lung cancer stage III – the Central European real-world experience

Ist Teil von

• Radiology and oncology, 2020-05, Vol.54 (2), p.209-220

Ort / Verlag

Poland: Sciendo

Erscheinungsjahr

2020

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Background Management of non-small-cell lung cancer (NSCLC) is affected by regional specificities. The present study aimed at determining diagnostic and therapeutic procedures including outcome of patients with NSCLC stage III in the real-world setting in Central European countries to define areas for improvements. Patients and methods This multicentre, prospective and non-interventional study collected data of patients with NSCLC stage III in a web-based registry and analysed them centrally. Results Between March 2014 and March 2017, patients (n=583) with the following characteristics were entered: 32% females, 7% never-smokers; ECOG performance status (PS) 0, 1, 2 and 3 in 25%, 58%, 12% and 5%, respectively; 21% prior weight loss; 53% squamous carcinoma, 38% adenocarcinoma; 10% EGFR mutations. Staging procedures included chest X-ray (97% of patients), chest CT (96%), PET-CT (27%), brain imaging (20%), bronchoscopy (89%), endobronchial ultrasound (EBUS) (13%) and CT-guided biopsy (9%). Stages IIIA/IIIB were diagnosed in 55%/45% of patients, respectively. N2/N3 nodes were diagnosed in 60%/23% and pathologically confirmed in 29% of patients. Most patients (56%) were treated by combined modalities. Surgery plus chemotherapy was administered to 20%, definitive chemoradiotherapy to 34%, chemotherapy only to 26%, radiotherapy only to 12% and best supportive care (BSC) to 5% of patients. Median survival and progression-free survival times were 16.8 (15.3;18.5) and 11.2 (10.2;12.2) months, respectively. Stage IIIA, female gender, no weight loss, pathological mediastinal lymph node verification, surgery and combined modality therapy were associated with longer survival. Conclusions The real-world study demonstrated a broad heterogeneity in the management o f stage III NSCLC in Central European countries and suggested to increase the rates of PET-CT imaging, brain imaging and invasive mediastinal staging.